PDF herunterladen
Semin Vasc Med 2005; 5(2): 183-189
DOI: 10.1055/s-2005-872403
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001 USA.

Homocysteine and Venous Thrombosis

Isabelle Quéré1 , Jean-Christophe Gris2 , Michel Dauzat3
  • 1Department of Vascular Medicine, Saint Eloi University Hospital, 80 Avenue Gaston Fliche, Montpellier, France
  • 2Department of Hematology, Montpellier 1 University, Nîmes, France
  • 3Department of Vascular Medicine, Montpellier 1 University, Nîmes, France
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
27. Juli 2005 (online)

    Lizenzen und Reprints

ABSTRACT

Elevated plasma total homocysteine concentration is a risk factor for venous thrombosis. The association is well established in patients with homocystinuria irrespective of the genetic etiology and metabolic background. Homocystinuria is a human model of chronic exposure to very high concentrations of plasma homocysteine and reflects an abnormal amino acid metabolism. Elevated homocysteine levels in patients with venous thrombosis have attracted considerable interest because homocysteine is a potentially reversible thrombophilic marker for venous thrombosis. In contrast to homocystinuria, hyperhomocysteinemia is mild and reflects environmental and constitutional factors such as age, intake of B-vitamins, derangements of metabolism, and renal impairment. This review examines the evidence for the relationship of homocysteine with risk of venous thrombosis in homocystinuria and in the general population.

KEYWORDS

Homocysteine - homocystinuria - venous thromboembolism - children - elderly - MTHFR

REFERENCES

  • 1 Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population.  J Intern Med. 1992;  232 155-160
    PubMedGoogle Scholar
  • 2 Hansson P O, Werlin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population.  Arch Intern Med. 1997;  157 1665-1670
    CrossrefPubMedGoogle Scholar
  • 3 Heit J A, Silverstein M D, Mohr D N et al.. The epidemiology of venous thromboembolism in the community.  Thromb Haemost. 2001;  86 452-463
    PubMedGoogle Scholar
  • 4 Mellemkjaer L, Sorensen H T, Dryere L, Olsen J, Olsen J H. Admission for and mortality from primary venous thromboembolism in women of fertile age in Denmark 1977-1995.  BMJ. 1999;  319 820-821
    CrossrefPubMedGoogle Scholar
  • 5 Chan A K, Deveber G, Monagle P, Brookers L A, Massicottes P M. Venous thrombosis in children.  J Thromb Haemost. 2003;  1 1443-1455
    CrossrefPubMedGoogle Scholar
  • 6 Homocysteine Lowering Trialist's Collaboration . Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials.  BMJ. 1998;  316 894-898
    PubMedGoogle Scholar
  • 7 Ehrenforth S, Junker R, Koch H G, Kreuz W, Müchow N, Scharrer I. Nowak-Göttl U for the Childhood Thrombophilia Study Group.  Eur J Pediatr. 1999;  158 S97-S104
    CrossrefPubMedGoogle Scholar
  • 8 van Ommen C H, Heijboer H, Büller H R, Hirasing R A, Heijmans H SA, Peters M. Venous thromboembolism in childhood: a prospective 2-year registry in the Netherlands.  J Pediatr. 2001;  139 676-681
    CrossrefPubMedGoogle Scholar
  • 9 Lawson S E, Butler D, Williams M D. Congenital thrombophilia and thrombosis: a study in a single centre.  Arch Dis Child. 1999;  81 176-178
    PubMedGoogle Scholar
  • 10 Tormene D, Simioni P, Prandoni P et al.. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study.  Blood. 2002;  100 2403-2405
    CrossrefPubMedGoogle Scholar
  • 11 Mudd S H, Skovby F, Levy H L et al.. The natural history of homocystinuria due to cystathionine beta-synthase deficiency.  Am J Hum Gene. 1985;  37 1-31
    PubMedGoogle Scholar
  • 12 Cochran F B, Sweetman L, Schmidt K, Barsch G, Kraus J, Packman S. Pyridoxine-unresponsive homocystinuria with an unusual clinical course.  Am J Med Genet. 1990;  35 519
    CrossrefPubMedGoogle Scholar
  • 13 Sanson B JS, Simioni P, Tormene D et al.. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of Antithrombin, Protein C or Protein S: a prospective cohort study.  Blood. 1999;  94 3702-3706
    PubMedGoogle Scholar
  • 14 Simioni P, Sanson B J, Prandoni P et al.. Incidence of venous thromboembolism in families with inherited thrombophilia.  Thromb Haemost. 1999;  81 198-202
    PubMedGoogle Scholar
  • 15 Buller H, Agnelli G, Hull R D, Prins M H, Raskob G E. Antithrombotic therapy for venous thromboembolism disease: the seventh ACCP Conference on antithrombotic and thrombolytic therapy.  Chest. 2004;  126 410-428
    PubMedGoogle Scholar
  • 16 Yap S, Boers G HJ, Wilcken B et al.. Vascular outcome in patients with homocystinuria due to CBS deficiency treated chronically. A multicenter observational study.  Arterioscler Thromb Vasc Biol. 2001;  21 2080-2085
    CrossrefPubMedGoogle Scholar
  • 17 Mandel H, Brenner B, Berant M et al.. Coexistence of hereditary homocystinuria and factor V Leiden-effect on thrombosis.  N Engl J Med. 1996;  334(12) 763-768
    CrossrefPubMedGoogle Scholar
  • 18 Quere I, Lamarti H, Chadefaux-Vekemans B. Thrombophilia, homocystinuria, and mutation of the factor V gene.  N Engl J Med. 1996;  335(4) 289
    CrossrefPubMedGoogle Scholar
  • 19 Kluijtmans L A, Boers G H, Verbruggen B, Trijbels F J, Novakova I R, Blom H J. Homozygous cystathionine beta-synthase deficiency, combined with factor V Leiden or thermolabile methylenetetrahydrofolate reductase in the risk of venous thrombosis.  Blood. 1998;  91(6) 2015-2018
    PubMedGoogle Scholar
  • 20 Yap S, O'Donnell K A, O'Neill C, Mayne P D, Thornton P, Naughten E. Factor V Leiden (Arg506Gln), a confounding genetic risk factor but not mandatory for the occurrence of venous thromboembolism in homozygotes and obligate heterozygotes for cystathionine beta-synthase deficiency.  Thromb Haemost. 1999;  81(4) 502-505
    PubMedGoogle Scholar
  • 21 Ogier de Baulny H, Gérard M, Saudubray J M, Zittoun J. Remethylation defects: guidelines for clinical diagnosis and treatment.  Eur J Padiatr. 1998;  157 S77-S83
    CrossrefPubMedGoogle Scholar
  • 22 Bodamer O AF, Rosenblatt D S, Appel S H, Beaudet A L. Adult-onset combined methylmalonic aciduria and homocystinuria.  Neurology. 2001;  56 1113
    PubMedGoogle Scholar
  • 23 Gaustadness M, Rüdiger N, Rasmussen K, Ingerslev J. Familial thrombophilia associated with homozygosity for the Cystathionine-β synthase 833T→C mutation.  Arterioscler Thromb Vasc Biol. 2000;  20 1392-1395
    PubMedGoogle Scholar
  • 24 Maclean K N, Gaustadness M, Oliveriusova J et al.. High homocysteine and thrombosis without connective tissue disorders are associated with a novel class of cystathionine-β synthase (CBS) mutations.  Hum Mutat. 2002;  19 641-655
    CrossrefPubMedGoogle Scholar
  • 25 Lievers K JA, Kluijtmans L AJ, Blom H J. Genetics of hyperhomocysteinemia in cardiovascular disease.  Ann Clin Biochem. 2003;  40 46-59
    CrossrefPubMedGoogle Scholar
  • 26 Refsum H, Smith A D, Ueland P M et al.. Facts and recommendations about total homocysteine determinations: an expert opinion.  Clin Chem. 2004;  50 3-32
    CrossrefPubMedGoogle Scholar
  • 27 Tallova J, Tomandl J, Bicikova M, Hill M. Changes of plasma total homocysteine levels during the menstrual cycle.  Eur J Clin Invest. 1999;  29 1041-1044
    CrossrefPubMedGoogle Scholar
  • 28 Murphy M M, Scott J M, McPartlin J M, Fernandez-Ballart J D. The pregnancy-related decrease in fasting plasma homocysteine is not explained by folic acid supplementation, hemodilution or a decrease in albumin in a longitudinal study.  Am J Clin Nutr. 2002;  76 614-619
    PubMedGoogle Scholar
  • 29 Morris M S, Jacques P F, Selhub J, Rosenberg I H. Total homocysteine and estrogen status in the Third National Health and Nutrition Examination Survey.  Am J Epidemiol. 2000;  152 140-148
    CrossrefPubMedGoogle Scholar
  • 30 Lacut K, Ogier E, Abalain J H, Moineau M P. Mottier D on behalf of the SARAH Investigators. Effects of oral and transdermal 17 β estradiol combined with progesterone on homocysteine metabolism in postmenopausal women: a randomised placebo-controlled trial.  Atherosclerosis. 2004;  174 173-180
    CrossrefPubMedGoogle Scholar
  • 31 Giri S, Thompson P D, Taxel P. Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men.  Atherosclerosis. 1998;  137 359
    CrossrefPubMedGoogle Scholar
  • 32 Giltay E J, Hoogeven E K, Elbers J MH, Goore L JG, Asscheman H, Stehouwer C DA. Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females.  J Clin Endocrinol Metab. 1998;  83 550-553
    CrossrefPubMedGoogle Scholar
  • 33 Martinelli I, Battaglioli P, Pedotti P, Cattaneo M, Mannucci P M. Hyperhomocysteinemia and cerebral vein thrombosis.  Blood. 2003;  102 1363-1366
    CrossrefPubMedGoogle Scholar
  • 34 Lahey J M, Kearney J J, Tunc M. Hypercoagulable states and central vein occlusion.  Curr Opin Pulm Med. 2003;  9 385-392
    CrossrefPubMedGoogle Scholar
  • 35 Brattstrom L, Tengborn L, Lagerstedt C et al.. Plasma homocysteine in venous thromboembolism.  Haemostasis. 1991;  21 51-57
    PubMedGoogle Scholar
  • 36 Bienvenu T, Ankri A, Chadefaux B et al.. Plasma homocysteine assay in the exploration of thrombosis in young subjects.  Presse Med. 1991;  20 985-988
    PubMedGoogle Scholar
  • 37 den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies.  J Thromb Haemost. 2005;  2 1-8
    PubMedGoogle Scholar
  • 38 Egerton W, Silberberg J, Crooks R, Ray C, Xie L, Dudman N. Serial measures of plasma homocysteine after acute myocardial infarction.  Am J Cardiol. 1996;  77 759-751
    CrossrefPubMedGoogle Scholar
  • 39 Murùa A, Quintana I, Galarza C, Alfie J, Kordich L. Unsuspected hyperhomocysteinemia in chronically anticoagulated patients.  Blood Coagul Fibrinolysis. 2001;  12 79-80
    CrossrefPubMedGoogle Scholar
  • 40 Ridker P M, Hennekens C H, Selhub J, Miletich J P, Malinow M R, Stampfer M J. Interrelation of hyperhomocyst(e)inemia, factor V Leiden and risk of future venous thromboembolism.  Circulation. 1997;  95 1777-1782
    CrossrefPubMedGoogle Scholar
  • 41 Tsai A W, Cushman M, Tsai M Y et al.. Serum homocysteine, MTHFR and venous thromboembolism: longitudinal investigation of thromboembolism etiology (LITE).  Am J Hematol. 2003;  72 192-200
    CrossrefPubMedGoogle Scholar
  • 42 Eichinger S, Stümpflen A, Hirschl M et al.. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism.  Thromb Haemost. 1998;  80 566-569
    PubMedGoogle Scholar
  • 43 Kluijtmans L AJ, Young I S, Boreham C A et al.. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults.  Blood. 2003;  101 2483-2488
    CrossrefPubMedGoogle Scholar
  • 44 Tsai M Y, Bignell M, Yang F, Welge B G, Graham K J, Hanson N Q. Polygenic influence on plasma homocysteine: association of two prevalent mutations, the 844ins68 of cystathionine b-synthase and A2756G methionine synthase with lowered plasma homocysteine levels.  Atherosclerosis. 2000;  149 131-137
    CrossrefPubMedGoogle Scholar
  • 45 Zetterberg H, Coppola A, D’Angelo A, Mona P, Rymo L, Blennow R. No association between the MTHFR A1298C and transcobalamin C677T genetic polymorphisms and hyperhomocysteinemia in thrombotic disease.  Thromb Res. 2003;  108 127-131
    PubMedGoogle Scholar
  • 46 Salomon O, Rosenberg N, Zivelin A et al.. Methionine synthase and methylenetetrahydrofolate reductase A1298C polymorphisms are not risk factors for idiopathic venous thromboembolism.  Hematol J. 2001;  2 38-41
    CrossrefPubMedGoogle Scholar
  • 47 Frosst P, Blom H J, Milos R et al.. A candidate genetic risk factor for vascular disease: a common mutation in methylene tetrahydrofolate reductase.  Nat Genet. 1995;  10 111-113
    CrossrefPubMedGoogle Scholar
  • 48 Hussemoer L L, Thomsen T F, Fenger M, Jorgensen H L, Jorgensen T. Contribution of thermolabile MTHF reductase variant to plasma homocysteine levels in healthy men and women. Inter(99).  Genet Epidemiol. 2003;  24 322-330
    CrossrefPubMedGoogle Scholar
  • 49 Wald D S, Law M, Morris J K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis.  BMJ. 2002;  325 1202-1206
    CrossrefPubMedGoogle Scholar
  • 50 De Stefano V, Casorelli I, Rossi E, Zappacosta B, Leone G. Interaction between hyperhomocysteinemia and Inherited Thrombophilic factors in venous Thromboembolism.  Sem Thromb Haemost. 2000;  26 305-311
    PubMedGoogle Scholar
  • 51 Quere I, Perneger T V, Zittoun J et al.. Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study.  Lancet. 2002;  359 747-752
    CrossrefPubMedGoogle Scholar
  • 52 Cattaneo M, Lombardi R, Lecchi A, Bucciarelli P, Mannucci P M. Low plasma levels of vitamin B(6) are independently associated with a heightened risk of deep-vein thrombosis.  Circulation. 2001;  104 2442-2446
    PubMedGoogle Scholar
  • 53 D’Angelo Armando . The role of vitB12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the MTHFR gene. A case-control study of patients with early-onset thrombotic events.  Thromb Haemost. 2000;  83 563-570
    PubMedGoogle Scholar
  • 54 Marcucci R, Brunelli T, Giusti B et al.. The role of cystene and homocysteine in venous and arterial thrombotic disease.  Am J Clin Pathol. 2001;  116 56-60
    CrossrefPubMedGoogle Scholar
  • 55 den Heijer M, Brouwer I A, Bos G MJ et al.. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers.  Arterioscl Thromb Vasc Biol. 1998;  18 356-261
    PubMedGoogle Scholar
  • 56 Willems H PJ, den Heijer M, Bos G MJ. Homocysteine and venous thrombosis: outline of a vitamin Intervention Trial.  Semin Thromb Haemost. 2000;  26 297-304
    PubMedGoogle Scholar

Isabelle QuéréM.D. 

Professor of Vascular Medicine, Department of Vascular Medicine

Saint Eloi University Hospital, 80 Avenue Gaston Fliche

34295 Montpellier Cedex 5, France